Biodefence Market Scope And Analysis

  • Report Code : TIPRE00005377
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Biodefense Market Scope and Analysis by 2031

Buy Now

Biodefense Market Report Biodefense Market Size and Share Biodefense Market Scope and Analysis

Biodefense Market Report Scope

Report Attribute Details
Market size in 2021 US$ 12.37 Billion
Market Size by 2031 US$ 21.62 Billion
Global CAGR (2023 - 2031) 6.1%
Historical Data 2021-2023
Forecast period 2024-2031
Segments Covered By Product
  • Anthrax
  • Smallpox
  • Botulism
  • Radiation
  • Nuclear
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Bavarian Nordic
  • Alnylam Pharmaceuticals Inc
  • SIGA Technologies
  • Emergent BioSolutions Inc
  • Cleveland Bio Labs
  • Dynavax Technologies
  • Elusys Therapeutics Inc
  • Soligenix
  • Altimmune
  • Pluristem
    		•

    Biodefense Market News and Recent Developments

    The biodefense market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for biodefense and strategies:

    • In February 2022, Appili Therapeutics Inc. announced funding of over US$ 10 million from the US Department of Defense, via the Joint Science and Technology Office of the Defense Threat Reduction Agency, to advance the company’s biodefense vaccine candidate, ATI-1701, a potential first-in-class vaccine candidate to prevent infection with Francisella tularensis. The funding is expected to boost the company's presence and increase growth in the biodefense market. (Source: Appili Therapeutics, Press Release, 2022)
    • In September 2022, Emergent BioSolutions Inc. completed its definitive agreement with Chimerix, Inc. to acquire Chimerix's exclusive global rights to TEMBEXA (brincidofovir), the first oral antiviral approved by the US Food and Drug Administration (FDA) for the treatment of smallpox in all age groups. (Source: Emergent BioSolutions Inc., News Release, 2022)
    • In July 2023, Emergent BioSolutions Inc. received approval from the US FDA for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in individuals 18 to 65 years of age when administered in conjunction with recommended antibacterial drugs. (Source: Emergent BioSolutions Inc., News Release, 2023)

    Biodefense Market Report Coverage and Deliverables

    The “Biodefense Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Market dynamics such as drivers, restraints, and key opportunities
    • Key future trends
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
    • Detailed company profiles